Tokyo, Sept 17, 2004 (JCN) - Sumitomo Pharmaceuticals, Co., Ltd. announces that it has concluded a license agreement with Novo Nordisk A/S (Denmark) for the anti-diabetic agent, Repaglinide (generic name) which will enable Sumitomo Pharmaceuticals to develop and market the drug in Japan.
Repaglinide is an anti-diabetic agent currently marketed by Novo Nordisk A/S in more than 80 countries in the world with the brand name "Prandin" in the USA "Gluconorm" in Canada and "NovoNorm" in other countries. The product is one in a group of anti-diabetic agents known as meglitinides, a rapid acting insulin secretagogue, which improves post-prandial blood glucose levels, an important parameter in the treatment of type 2 diabetes. This is achieved by increasing insulin secretion after meals.
With this agreement, Sumitomo Pharmaceuticals now takes over the development of Repaglinide in Japan, previously initiated by Novo Nordisk Pharma Ltd., the Japanese subsidiary of Novo Nordisk A/S.
Type 2 diabetes is a lifestyle-related disease, with the number of people affected by it going up worldwide. This therapeutic area is an important R&D target for Sumitomo Pharmaceuticals, which has "Glucophage" (metformin), licensed from Merck Sante s.a.s., in the development stage and several other development candidates in the R&D pipeline. Sumitomo Pharmaceuticals also has "Melbin", a metformin product in the market already and an application has been filed for the introduction of a smaller size tablet.
Sumitomo Pharmaceuticals has planned to conduct all necessary clinical studies to achieve early launch of Repaglinide, and wishes to contribute to better treatment of diabetic patients by adding Repaglinide to its product pipeline.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Sumitomo Chemical Files Suit Against Pfizer for Amlodipine Besilate
(Nov 2, 2005)
|
|
|
Dainippon Sumitomo Pharma Kicks off Operations
(Oct 3, 2005)
|
|
|
Sumitomo Pharmaceuticals, Merck to Form Global Partnership for Atypical Antipsychotic Compound SM-13496
(July 8, 2005)
|
|
|
Sumitomo Pharmaceuticals, Conforma Therapeutics Conclude Licensing Agreement for Antitumor Agent, Amrubicin Hydrocholoride
(July 1, 2005)
|
|
|
Sumitomo Pharmaceuticals, Protez Pharmaceutical Conclude Licensing Agreement for SMP-601 Antibiotic Candidate
(May 23, 2005)
|
|
|
Dainippon Pharmaceutical, Sumitomo Pharmaceuticals Announce Details of Upcoming Merger
(May 19, 2005)
|
|
|
Olympus Biomaterial to Take over Sumitomo's Bone Replacement Material Business
(May 11, 2005)
|
|
|
Dainihon Jochugiku to Acquire Sumitomo Pharmaceuticals Healthcare As Its Wholly Owned Subsidiary
(May 2, 2005)
|
|
|
UCB Japan Announces Sales Channel Change of Zyrtec Tablet in Japan
(Apr 19, 2005)
|
|
|
Sumitomo Chemical Increases Its Share in Sumitomo Pharmaceuticals
(Apr 18, 2005)
|
|
|
